Integra LifeSciences reported a challenging fourth quarter and full year, marked by revenue declines and lower GAAP earnings, primarily due to ongoing remediation efforts and operational challenges. The company is implementing a transformation plan focused on a simplified operating model and portfolio prioritization to drive future margin improvement and sustainable growth.
Codman Specialty Surgical segment revenues increased 2.7% on a reported basis and 1.6% on an organic basis in Q4.
positiveAdjusted EBITDA margin improved to 24.0% in Q4 2025 from 23.7% in Q4 2024.
positiveThe company is implementing a simplified operating model expected to yield $25-$30 million in savings in 2026.
positiveTotal reported revenues decreased 1.7% to $434.9 million in Q4 2025, with organic revenues down 2.5%.
negativeFull-year reported revenues increased only 1.5% to $1,635.2 million, with organic sales down 0.7%.
negativeGAAP net loss widened significantly to $(516.5) million in FY2025, driven by a $511 million goodwill impairment charge.
negativeAdjusted diluted EPS decreased to $0.83 in Q4 2025 from $0.97 in Q4 2024, and to $2.23 for FY2025 from $2.56 in FY2024.
negativeTissue Technologies segment revenues decreased 12.8% on a reported and organic basis in Q4, primarily due to remediation efforts for MediHoney® and a challenging comparison for Integra Skin.
negativeFull-year adjusted EBITDA decreased to $317.5 million from $322.2 million in the prior year, with margins declining 60 basis points.
negativeQ1 2026 reported revenue guidance is expected to be between $375 million to $390 million, representing a potential decrease of up to 2.0% on a reported basis.
attentionInventory levels increased to $492.7 million from $429.1 million YoY.
attentionNet debt increased to $1.6 billion at the end of 2025 from $1.5 billion at the end of 2024.
attentionAdjusted Free Cash Flow was negative for both Q4 2025 (-$5.4 million) and FY2025 (-$31.1 million).
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Codman Specialty Surgical | N/A | — | — | — |
Tissue Technologies | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
In the fourth quarter, we drove tangible operational progress while continuing to deliver for our customers and patients.
During 2025, we further strengthened our quality management system, advanced our Compliance Master Plan, and progressed execution of our remediation work.
Our operational and execution focus resulted in significant outcomes in key areas, namely Integra Skin supply reliability, healthier safety stock levels across our portfolio, and early relaunch of PriMatrix and Durepair.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.